Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | STK3 | Q13188 | 2/20 | 0.41 |
| ▸ | STK4 | Q13043 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13612242 | 0.94 | ERBB2 (0.52) | EGFRERBB2LCKKCNH2STK3 | |
| SCHEMBL13611880 | 0.93 | ERBB2 (0.46) | EGFRERBB2LCKKCNH2STK3 | |
| SCHEMBL13611886 | 0.91 | EGFR (0.50) | EGFRERBB2LCKKCNH2 | |
| SCHEMBL13612198 | 0.86 | EGFR (0.49) | EGFRERBB2LCKKCNH2 | |
| SCHEMBL13612032 | 0.85 | ERBB2 (0.45) | EGFRERBB2LCKKCNH2STK3 | |
| SCHEMBL13612247 | 0.85 | EGFR (0.45) | EGFRERBB2LCKKCNH2 | |
| SCHEMBL13612635 | 0.83 | ERBB2 (0.50) | EGFRERBB2LCKKCNH2 | |
| SCHEMBL13611889 | 0.82 | EGFR (0.46) | EGFRERBB2LCKKCNH2STK3 | |
| SCHEMBL13612189 | 0.81 | STK4 (0.41) | EGFRERBB2STK3STK4 | |
| SCHEMBL13612617 | 0.81 | ERBB2 (0.45) | EGFRERBB2LCKKCNH2STK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625908-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20070244136-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244136-A1 | Quinazoline Derivatives | ERBB2, ABL1, MKI67 | EGFR 10/4885ERBB2 1/4885LCK 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.